Exagen (XGN) to Release Quarterly Earnings on Tuesday

Exagen (NASDAQ:XGN) will likely be announcing its earnings results before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $13.85 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Exagen Stock Performance

NASDAQ XGN opened at $3.06 on Tuesday. The firm has a 50-day moving average of $3.98 and a 200-day moving average of $3.57. The company has a debt-to-equity ratio of 1.54, a quick ratio of 4.05 and a current ratio of 4.05. The stock has a market cap of $53.97 million, a PE ratio of -3.26 and a beta of 1.41. Exagen has a 52-week low of $1.30 and a 52-week high of $6.22.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on XGN shares. Canaccord Genuity Group raised their target price on shares of Exagen from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. William Blair restated an “outperform” rating on shares of Exagen in a research note on Wednesday, November 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $8.00 price objective on shares of Exagen in a research note on Monday, January 13th.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).